Kestra Medical is the first commercial challenger to make a visible dent in Zoll Medical's long hold on wearable cardioverter defibrillators, the vest-like devices that sit on a recovering heart patient and deliver a shock if a lethal rhythm appears. Fiscal 2026 is the first full public year in which that challenge shows up as more than a prospectus story. Revenue reached $95 million and prescriptions rose fifty-seven percent, while full-year gross margin crossed fifty percent for the first time. The debate is not whether the product works. The debate is whether share gains, in-network mix, and the ACE-PAS evidence set compound into a self-funding franchise before commercial spend, a still-dominant incumbent, and a new adhesive device force another trip to the equity window.
The year that matters is the one that converted clinical permission into commercial velocity. In November, primary results from the ASSURE WCD Clinical Evaluation Post-Approval Study landed as late-breaking science at the American Heart Association meeting, giving hospital systems a real-world conversion and safety data set that Zoll no longer owns alone. In December the company sold 6.9 million common shares and raised about $149 million of net proceeds, buying time to staff territories rather than ration them. In July a five-year facility with funds managed by Pharmakon Advisors replaced the older Perceptive credit line and added committed dry powder against revenue milestones. Those three events sit on one mechanism: Kestra is paying cash today to occupy a category that has been a near-monopoly for a generation, and the unit economics only work if the vest stays on the patient and the claim stays in network.
What the market is already paying for is continued mid-forties growth on the way to the $137 million fiscal 2027 revenue plan, with gross margin holding above fifty percent. What the market is not yet forcing is proof that selling, general, and administrative spend can stop outrunning gross profit. Adjusted operating expense still swamps the contribution from each incremental prescription, and the full-year operating cash outflow barely improved even as the fourth-quarter burn rate eased. The forward question is whether prescription share and in-network mix keep compounding fast enough for the contribution margin to absorb the commercial build, or whether Zoll and the May-approved adhesive entrant recapture accounts before that crossing arrives.